secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-05-26T20:05:16+00:00
Accession:  0001193125-26-239246
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian inks commercial manufacturing deal with WuXi Biologics for veligrotug
------------------------------------------------------------------------------

- Agreement covers long-term supply of veligrotug drug substance and drug product, if approved.
- WuXi Biologics is non-exclusive supplier; Viridian may use alternate manufacturers.
- Initial term of 5 years, auto-renewing for successive 5-year periods unless 24-month non-renewal notice given.
- Volume-based pricing fixed through Dec 31, 2026, then annually adjustable; pass-through costs reimbursed.
- Company may terminate on 30 days' notice for change in law materially impacting WuXi's performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/0001193125-26-239246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/d111034d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-239246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer